Table of Content

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. High prevalence of chronic disease
4.1.1.2. Rising demand for infection control measure
4.1.2. Restraints:
4.1.2.1. Side Effects associated with vaccines
4.1.3. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion

7. By Vaccines Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Type Segment
7.1.2. Market Attractiveness Index, By Vaccines Type
7.2. Live-attenuated*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Inactivated
7.4. Conjugate
7.5. Toxoid
7.6. Others

8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Intravenous
8.4. Others

9. By Disease
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
9.1.2. Market Attractiveness Index, By Disease
9.2. Measles*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Influenza
9.4. Smallpox
9.5. Yellow fever
9.6. Hepatitis A
9.7. Polio
9.8. Shingles
9.9. COVID-19
9.10. Others

10. By Age
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Segment
10.1.2. Market Attractiveness Index, By Age Segment
10.2. Pediatrics*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Adults
10.4. Geriatrics

11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
11.3. Retail Pharmacies
11.4. Online Pharmacies

12. By Region
12.1. Introduction
12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. The U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape
13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Treatment type Benchmarking

14. Company Profiles
14.1. Merck&Co., Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Key Highlights
14.1.4. Financial Overview
14.2. Emergent Bio solutions
14.3. GlaxoSmithKline
14.4. Novartis
14.5. Sanofi Pasteur
14.6. Seqirus
14.7. Pfizer
14.8. CSL Limited
14.9. Jhonson & Jhonson
14.10. Serum Institute of India Pvt Ltd. (*LIST NOT EXHAUSTIVE)
15. DataM Intelligence
15.1. Appendix
15.2. About Us and Services
15.3. Contact US